Glaxosmithkline Pharmaceuticals Ltd (GLAXO)
₹2,949.60
Mkt cap
₹50,112 Cr
P/E ratio
47.60
P/B
22.01
Div yield
1.93%
ROE
45.60%
ROCE
61.40%
EPS (TTM)
₹61.97
Book value
₹134
52W range
2,103–3,106
Sector
Healthcare
Price history
Previous close
GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)
NSE GLAXOBSE 500660
Health check
Mixed
ValuationExpensive
ProfitabilityStrong
GrowthLow
TechnicalsBullish
52-week range
−5.05% from high₹2,950
₹2,103+40.24% from low₹3,106
Current
₹2,949.60
Prev close
₹2,954.00
Day
−0.15%
Price performance
1D
−0.15%
1W
−3.29%
1M
+13.46%
3M
+34.40%
6M
+18.65%
1Y
+5.02%
YTD
+18.75%
Financials
Revenue, profit & margin
P/E ratio
47.6×
GLAXO is 40% above the sector median of 34.0×
GLAXO47.6×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 762 | 957 | 805 | 930 | 815 | 1,011 | 949 | 974 | 805 | 980 | 1,041 | 995 | 938 | |
| Expenses | 618 | 668 | 587 | 673 | 584 | 689 | 658 | 641 | 554 | 644 | 670 | 644 | 643 | |
| Operating Profit | 144 | 289 | 218 | 257 | 231 | 322 | 292 | 333 | 251 | 336 | 371 | 351 | 296 | |
| OPM % | 19% | 30% | 27% | 28% | 28% | 32% | 31% | 34% | 31% | 34% | 36% | 35% | 31% | |
| Other Income | 54 | 28 | -135 | 32 | 36 | 39 | 35 | 41 | 44 | 36 | 50 | 36 | 44 | |
| Interest | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | |
| Depreciation | 16 | 18 | 17 | 18 | 16 | 17 | 19 | 15 | 16 | 17 | 20 | 13 | 16 | |
| Profit before tax | 181 | 299 | 65 | 271 | 249 | 344 | 308 | 359 | 279 | 354 | 400 | 373 | 322 | |
| Tax % | 27% | 27% | 30% | 28% | 27% | 27% | 25% | 27% | 27% | 27% | 26% | 26% | 26% | |
| Net Profit | 132 | 218 | 46 | 194 | 182 | 252 | 230 | 263 | 205 | 257 | 296 | 278 | 237 | |
| EPS in Rs | 7.81 | 12.84 | 2.70 | 11.48 | 10.76 | 14.91 | 13.57 | 15.52 | 12.10 | 15.20 | 17.45 | 16.40 | 14.00 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.18% · closed higher next day 21 of last 44
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 9 Nov '23◦ | 12 Feb '24◦ | 17 May '24◦ | 2 Aug '24◦ | 30 Oct '24 | 14 Feb '25◦ | 13 May '25◦ | 1 Aug '25 | 6 Nov '25◦ | 9 Feb '26 | 13 May '26 | 3 Aug '26◦ |
| Earnings day | +1.55% | −6.86% | +3.17% | −2.00% | +1.70% | +15.97% | +3.23% | −7.15% | −0.68% | +1.30% | −1.52% | −0.57% |
| +1 day | +1.50% | −7.98% | +2.51% | −1.09% | +3.14% | +25.71% | +3.23% | −9.28% | −2.52% | +5.59% | −1.31% | −3.48% |
| +5 days | +13.70% | −2.18% | +3.24% | +2.48% | −0.69% | +30.73% | +7.01% | −16.18% | −4.84% | +4.56% | −4.17% | −2.27% |
| +15 days | +16.72% | −8.96% | +13.74% | +1.91% | −10.95% | +31.64% | +22.64% | −11.40% | −1.38% | +1.96% | −11.52% | +11.31% |
| +30 days | +24.86% | −16.82% | +14.51% | −0.76% | −13.35% | +41.56% | +16.86% | −13.42% | −2.94% | −7.04% | −3.84% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 57 Per Share | 57.00 | 29 May '26 | 29 May '26 |
Shareholding
as of Jun 202675.00%Promoter
Promoters75.00%
FIIs4.79%0.17
DIIs7.81%0.13
Public12.42%0.27
Government0.00%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| GLAXO | ₹2,958.10 | 47.59 | 50,112 | 1.93% | 237 | +15.69% | 938 | +16.55% | 61.41% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013nseAnnual Report 2013bse
Concall transcripts25
TranscriptAug 2026PPTAug 2026TranscriptJun 2026PPTJun 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptOct 2024TranscriptAug 2024TranscriptMay 2024TranscriptFeb 2024PPTFeb 2024TranscriptMar 2023TranscriptAug 2022PPTAug 2022PPTAug 2021
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 2 SepCorrigendum To The Notice Of Postal Ballot Dated August 3, 2026 1 SepVolume Movement Letter 26 Aug - Company says recent share volume spike is market-driven, with no undisclosed material information.Clarification sought from GlaxoSmithKline Pharmaceuticals Ltd 26 Aug - Exchange has sought clarification from GlaxoSmithKline Pharmaceuticals Ltd on August 26, 2026, with reference to Movement in Volume.Disclosure Under Regulation 30 19 Aug - GSK received Rs 4.99 crore income tax refund for AY 2025-26.